

Prefilled Syringes Market by Type (Conventional, Safety), Material (Glass Prefilled Syringe, Plastic), Design (Single-Chamber Prefilled Syringe, Dual-Chamber), Application (Diabetes, Cancer, and Rheumatoid Arthritis), & Region - Global Forecast to 2030

Market Report | 2024-07-29 | 293 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The prefilled syringes market is projected to reach USD 13.1 billion by 2030 from USD 7.1 billion in 2024, at a CAGR of 10.8% during the forecast period. The prefilled syringes market has had strong growth due to a number of factors such as the rising incidences of chronic diseases like diabetes, rheumatoid arthritis, and cardiovascular disorders. Moreover, prefilled syringes make it easier to administer medications precisely and consistently to patients with chronic conditions, by providing ready-to-use doses that improve patient compliance and lower the possibility of dosage errors. Additionally, the growing trend of self-administration has also played a major role in the market's growth. Prefilled syringes are preferred by patients due to their comfort and ease of use, as they eliminate the need for dose measurement, hence improving safety and lowering the danger of contamination. "By type, conventional prefilled syringes segment is expected to have the largest market share in the prefilled syringes market." Based on the type, the conventional prefilled syringes segment is expected to dominate the prefilled syringes market due to several factors. Their ready-to-use nature and pre-measured doses enhance convenience and safety by reducing preparation time and dosing errors. They lower contamination risks and needle stick injuries through advanced safety features. Prefilled syringes improve patient compliance, particularly for chronic conditions, by being user-friendly and encouraging adherence to treatment regimens. Their versatility in therapeutic applications, especially for biologics and chronic disease treatments, coupled with the growing prevalence of such conditions, further drive their market dominance.

"By material, glass prefilled syringes segment is expected to have the largest market share in the prefilled syringes market." Based on material, the glass prefilled syringe segment is expected to hold the largest market share in the prefilled syringes

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

market. Their superior chemical inertness ensures drug stability and reduces the risk of interactions between the drug and the container, making them ideal for a wide range of pharmaceutical applications. Additionally, glass syringes offer high visibility, allowing for easy inspection of the drug for particulates and discoloration, which is critical for quality control and patient safety. As a result, pharmaceutical companies and healthcare providers prefer glass prefilled syringes for their reliability, safety, and efficiency in drug delivery.

"By design, single-chamber prefilled syringes segment is expected to have the largest market share in the prefilled syringes market."

Based on design, the single-chamber prefilled syringe segment accounted for the largest market share of the prefilled syringes market due to their convenience, safety, and efficiency in drug administration. These syringes, which come pre-loaded with a single dose of medication, minimize the risk of dosing errors and contamination, enhancing patient safety. They streamline the injection process, making it quicker and easier for healthcare providers and patients, thereby improving compliance and treatment outcomes. Moreover, their widespread adoption in various therapeutic areas, particularly in chronic disease management and emergency care, further drives growth in the market.

"By application, cancer segment is expected to have the largest market share in the prefilled syringes market."

By application, the cancer segment is expected to hold the largest market share due to the increasing prevalence of cancer globally and the rising need for advanced drug delivery systems. Prefilled syringes offer significant advantages for cancer treatment, including precise dosing, reduced risk of contamination, and enhanced patient safety and compliance. As cancer treatments often involve complex medication regimens requiring regular and accurate administration, the convenience and reliability of prefilled syringes become critical. Additionally, advancements in biologics and targeted therapies, which are frequently used in oncology, further drive the demand for prefilled syringes, making the cancer segment the dominant application area in this market.

"By region, North American region is expected to have the largest market share in the prefilled syringes market."

North America to register for the highest share of the prefilled syringes market during the forecast period due to several factors. These include a well-established healthcare infrastructure, high adoption rates of advanced medical technologies, and a significant focus on patient safety and convenience. Moreover, the region benefits from robust regulatory frameworks that encourage the adoption of pre-filled syringes by ensuring stringent quality standards and safety measures. Additionally, increasing incidences of chronic diseases requiring regular injections, coupled with rising healthcare expenditures, contribute to the growing demand for pre-filled syringes in North America. The presence of major pharmaceutical companies and biotechnology firms further enhances market growth through extensive research and development activities aimed at improving drug delivery systems.

A breakdown of the primary participants (supply-side) for the prefilled syringes market referred to for this report is provided below:

-□By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3-25%

-□By Designation: C-level-20%, Director Level-35%, and Others-45%

-□By Region: North America-27%, Europe-25%, Asia Pacific-30%, Latin America- 8%, Middle East & Africa-10% .

Prominent players in the prefilled syringes market are BD (US), Gerresheimer AG (Germany), SCHOTT (Germany), and West Pharmaceutical Services, Inc. (US), AptarGroup Inc. (US), Nipro (Japan), Baxter (US), Owen Mumford Ltd. (UK), Weigao Medical International Co., Ltd. (China), Credence MedSystems, Inc.(US), Novartis AG (Switzerland), Stevanato Group (Italy), Polymedure (India), MedXL (Canada), Sharps Technology, Inc.(US), Fresenius Kabi (US), DBM S.R.L. (Italy), Taisei Kako Co.,Ltd (Japan), Shandong Province Medicinal Glass Co., Ltd.(China), SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD (Japan), J.O. PHARMA CO., LTD. (Japan), BIKOREA (Korea), B. Braun SE (Germany), and Al Shifa Medical Products Co. (Saudi Arabia).

Research Coverage:

The report analyzes the prefilled syringes market and aims at estimating the market size and future growth potential of this

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

market based on various segments such as type, material, design, application, and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall prefilled syringes market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

- Analysis of key drivers (increasing chronic diseases, incereasing biologics and biosimilars, and technological advancements), restraints (product recalls, and stringent government regulations), opportunities (increasing prevalence of self-administration of injectables and increasing regulatory support) and challenges (presence of alternative drug delivery methods, and infections associated with needlestick injuries)
- Market Penetration: It includes extensive information on products offered by the major players in the global the prefilled syringes market. The report includes various segments in type, material, design, application, and region.
- Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global prefilled syringes market.
- Market Development: Thorough knowledge and analysis of the profitable rising markets by type, materila, design, application, and region.
- Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the prefilled syringes market.
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global prefilled syringes market.

Table of Contents:

| | |
|--|----|
| 1□INTRODUCTION□ | 24 |
| 1.1□STUDY OBJECTIVES□ | 24 |
| 1.2□MARKET DEFINITION□ | 24 |
| 1.2.1□INCLUSIONS & EXCLUSIONS□ | 25 |
| 1.3□STUDY SCOPE□ | 26 |
| 1.4□YEARS CONSIDERED□ | 27 |
| 1.5□CURRENCY CONSIDERED□ | 27 |
| 1.6□STAKEHOLDERS□ | 28 |
| 1.7□SUMMARY OF CHANGES□ | 28 |
| 2□RESEARCH METHODOLOGY□ | 30 |
| 2.1□RESEARCH DATA□ | 30 |
| 2.1.1□SECONDARY DATA□ | 31 |
| 2.1.1.1□Key data from secondary sources□ | 31 |
| 2.1.2□PRIMARY DATA□ | 32 |
| 2.1.2.1□Key data from primary sources□ | 33 |
| 2.1.2.2□Key industry insights□ | 34 |
| 2.2□MARKET SIZE ESTIMATION□ | 36 |
| 2.3□MARKET BREAKDOWN & DATA TRIANGULATION□ | 41 |
| 2.4□MARKET SHARE ESTIMATION□ | 42 |
| 2.5□STUDY ASSUMPTIONS□ | 42 |
| 2.6□LIMITATIONS□ | 42 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|---------|--|----|
| 2.6.1 | METHODOLOGY-RELATED LIMITATIONS | 43 |
| 2.7 | RISK ASSESSMENT | 43 |
| 2.8 | IMPACT OF RECESSION ON PREFILLED SYRINGES MARKET | 43 |
| 3 | EXECUTIVE SUMMARY | 45 |
| 4 | PREMIUM INSIGHTS | 50 |
| 4.1 | PREFILLED SYRINGES MARKET OVERVIEW | 50 |
| 4.2 | ASIA PACIFIC: PREFILLED SYRINGES MARKET OVERVIEW | 51 |
| 4.3 | PREFILLED SYRINGES MARKET: REGIONAL MIX | 52 |
| 4.4 | PREFILLED SYRINGES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES | 53 |
| 4.5 | PREFILLED SYRINGES MARKET: DEVELOPED VS. EMERGING ECONOMIES | 54 |
| | | |
| 5 | MARKET OVERVIEW | 55 |
| 5.1 | INTRODUCTION | 55 |
| 5.2 | MARKET DYNAMICS | 55 |
| 5.2.1 | DRIVERS | 56 |
| 5.2.1.1 | Increasing prevalence of chronic diseases | 56 |
| 5.2.1.2 | Growing adoption of self-injection devices | 56 |
| 5.2.1.3 | Increasing adoption of prefilled syringes in parenteral dosage forms | 57 |
| 5.2.1.4 | Increased use of biologics and vaccines | 58 |
| 5.2.1.5 | Technological advancements in prefilled syringes | 58 |
| 5.2.2 | RESTRAINTS | 59 |
| 5.2.2.1 | Stringent government regulations | 59 |
| 5.2.2.2 | Impact of product recalls | 59 |
| 5.2.3 | OPPORTUNITIES | 60 |
| 5.2.3.1 | Growing preference for unit-dose medication using prefilled syringes | 60 |
| 5.2.3.2 | Emerging markets with growing healthcare infrastructure | 60 |
| 5.2.4 | CHALLENGES | 61 |
| 5.2.4.1 | Alternative drug delivery methods | 61 |
| 5.2.4.2 | Infections associated with needlestick injuries | 62 |
| 5.3 | INDUSTRY TRENDS | 62 |
| 5.3.1 | PREFILLED BIOLOGICS | 62 |
| 5.3.2 | INTEGRATED SAFETY FEATURES | 63 |
| 5.4 | TECHNOLOGY ANALYSIS | 63 |
| 5.4.1 | KEY TECHNOLOGIES | 63 |
| 5.4.1.1 | Integration disinfection unit (IDU) | 63 |
| 5.4.2 | COMPLEMENTARY TECHNOLOGIES | 64 |
| 5.4.2.1 | Cyclic olefin polymers (COP) and cyclic olefin copolymers (COC) | 64 |
| 5.4.3 | ADJACENT TECHNOLOGIES | 64 |
| 5.4.3.1 | Integration with autoinjectors | 64 |
| 5.5 | VALUE CHAIN ANALYSIS | 65 |
| 5.6 | PORTER'S FIVE FORCES ANALYSIS | 66 |
| 5.6.1 | THREAT OF NEW ENTRANTS | 67 |
| 5.6.2 | THREAT OF SUBSTITUTES | 67 |
| 5.6.3 | BARGAINING POWER OF SUPPLIERS | 67 |
| 5.6.4 | BARGAINING POWER OF BUYERS | 67 |
| 5.6.5 | INTENSITY OF COMPETITIVE RIVALRY | 67 |
| 5.7 | REGULATORY LANDSCAPE | 68 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|---------|---|-----|
| 5.7.1 | REGULATORY ANALYSIS | 68 |
| 5.7.2 | REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS | 68 |
| | ? | |
| 5.8 | CASE STUDY ANALYSIS | 71 |
| 5.8.1 | CASE STUDY 1: ENVIRONMENTAL BENEFITS OF USING PREFILLED 'EMERGENCY' DRUGS | 71 |
| 5.8.2 | CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION | 72 |
| 5.9 | PRICING ANALYSIS | 72 |
| 5.9.1 | AVERAGE SELLING PRICE OF PREFILLED SYRINGES, BY TYPE, 2022-2024 | 72 |
| 5.9.2 | AVERAGE SELLING PRICE TREND, BY REGION, 2022-2024 | 73 |
| 5.10 | UNMET NEEDS | 73 |
| 5.11 | ECOSYSTEM ANALYSIS | 74 |
| 5.12 | SUPPLY CHAIN ANALYSIS | 75 |
| 5.13 | ADJACENT MARKET ANALYSIS | 76 |
| 5.14 | TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES | 77 |
| 5.15 | TRADE ANALYSIS | 78 |
| 5.16 | PATENT ANALYSIS | 79 |
| 5.16.1 | PATENT PUBLICATION TRENDS FOR PREFILLED SYRINGES | 79 |
| 5.16.2 | INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS | 80 |
| 5.16.3 | TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR PREFILLED SYRINGE PATENTS (JANUARY 2014?APRIL 2024) | 81 |
| 5.16.4 | TOP APPLICANT COUNTRIES/REGIONS PATENTS FOR PREFILLED SYRINGES (JANUARY 2014?APRIL 2024) | 81 |
| 5.17 | KEY CONFERENCES & EVENTS DURING 2024-2025 | 83 |
| 5.18 | KEY STAKEHOLDERS & BUYING CRITERIA | 84 |
| 5.18.1 | KEY STAKEHOLDERS IN BUYING PROCESS | 84 |
| 5.18.2 | BUYING CRITERIA | 85 |
| 5.19 | INVESTMENT & FUNDING SCENARIO | 86 |
| 5.20 | REIMBURSEMENT SCENARIO | 86 |
| 5.21 | MARKET ANALYSIS OF PREFILLED SYRINGE COMPONENTS | 87 |
| 5.21.1 | PLUNGER STOPPERS | 87 |
| 6 | PREFILLED SYRINGES MARKET, BY TYPE | 89 |
| 6.1 | INTRODUCTION | 90 |
| 6.2 | CONVENTIONAL PREFILLED SYRINGES | 90 |
| 6.2.1 | DISPOSABLE PREFILLED SYRINGES | 93 |
| 6.2.1.1 | Increasing focus on patient safety to drive market | 93 |
| 6.2.2 | REUSABLE PREFILLED SYRINGES | 95 |
| 6.2.2.1 | Cost-effectiveness and technological advancements to drive market | 95 |
| 6.3 | SAFETY PREFILLED SYRINGES | 97 |
| 6.3.1 | INTEGRATED SAFETY FEATURES TO BOOST ADOPTION | 97 |
| | ? | |
| 7 | PREFILLED SYRINGES MARKET, BY DESIGN | 99 |
| 7.1 | INTRODUCTION | 100 |
| 7.2 | SINGLE-CHAMBER PREFILLED SYRINGES | 100 |
| 7.2.1 | CONVENIENCE, SAFETY, AND EFFICIENCY OF SINGLE-CHAMBER SYRINGES TO SUPPORT MARKET GROWTH | 100 |
| 7.3 | DUAL-CHAMBER PREFILLED SYRINGES | 102 |
| 7.3.1 | UNIQUE ADVANTAGES AND SPECIFIC APPLICATIONS OF DUAL-CHAMBER SYRINGES TO DRIVE DEMAND | 102 |
| 7.4 | CUSTOMIZED PREFILLED SYRINGES | 104 |
| 7.4.1 | PATIENT-FRIENDLY FEATURES SUCH AS EASY-TO-READ DOSAGE INDICATORS AND SAFETY MECHANISMS TO BOOST | |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

ADOPTION104

8 PREFILLED SYRINGES MARKET, BY MATERIAL106

8.1 INTRODUCTION107

8.2 GLASS PREFILLED SYRINGES107

8.2.1 ABILITY OF GLASS PREFILLED SYRINGES TO OFFER SUPERIOR BARRIER PROPERTIES TO BOOST MARKET GROWTH107

8.3 PLASTIC PREFILLED SYRINGES109

8.3.1 IMPROVED SAFETY, COST-EFFECTIVENESS, VERSATILITY, AND CONVENIENCE OF PLASTIC SYRINGES TO SUPPORT ADOPTION109

9 PREFILLED SYRINGES MARKET, BY APPLICATION111

9.1 INTRODUCTION112

9.2 DIABETES112

9.2.1 INCREASING PREVALENCE OF DIABETES TO FAVOR MARKET GROWTH112

9.3 RHEUMATOID ARTHRITIS114

9.3.1 RISING DEMAND FOR EFFECTIVE AND CONVENIENT TREATMENT OPTIONS FOR RHEUMATOID ARTHRITIS TO DRIVE MARKET114

9.4 ANAPHYLAXIS115

9.4.1 CONVENIENCE OF PREFILLED SYRINGES TO ADMINISTER MEDICATION QUICKLY DURING ANAPHYLACTIC EPISODES TO BOOST GROWTH115

9.5 CANCER117

9.5.1 RISING GLOBAL CANCER RATES TO SUPPORT MARKET GROWTH117

9.6 THROMBOSIS119

9.6.1 MINIMIZED RISK OF CONTAMINATION AND INFECTION ASSOCIATED WITH PREFILLED SYRINGES TO DRIVE DEMAND119

9.7 OPHTHALMOLOGY121

9.7.1 FEWER SIDE-EFFECTS ASSOCIATED WITH PREFILLED SYRINGES COMPARED TO TOPICAL MEDICATIONS TO SUPPORT GROWTH121

9.8 OTHER APPLICATIONS122

?

10 PREFILLED SYRINGES MARKET, BY REGION123

10.1 INTRODUCTION124

10.2 NORTH AMERICA125

10.2.1 NORTH AMERICA: RECESSION IMPACT126

10.2.2 US130

10.2.2.1 US to dominate North American prefilled syringes market130

10.2.3 CANADA133

10.2.3.1 Increasing government support and rising incidence of chronic diseases to drive market133

10.3 EUROPE136

10.3.1 EUROPE: RECESSION IMPACT138

10.3.2 GERMANY140

10.3.2.1 Germany to dominate market in Europe140

10.3.3 UK143

10.3.3.1 Growing number of CVD and diabetes patients to drive market growth143

10.3.4 FRANCE146

10.3.4.1 Increasing needlestick injuries and growing trend of self-administration to drive market growth146

10.3.5 SPAIN149

10.3.5.1 Increase in biologics production to support market growth149

10.3.6 ITALY152

10.3.6.1 Growing focus of pharmaceutical and medical device companies to boost market growth152

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|----------|---|-----|
| 10.3.7 | REST OF EUROPE (ROE) | 155 |
| 10.4 | ASIA PACIFIC | 158 |
| 10.4.1 | ASIA PACIFIC: RECESSION IMPACT | 162 |
| 10.4.2 | JAPAN | 163 |
| 10.4.2.1 | Increased geriatric population and favorable government initiatives to drive market growth in Japan | 163 |
| 10.4.3 | CHINA | 165 |
| 10.4.3.1 | Rising prevalence of chronic diseases to augment market growth | 165 |
| 10.4.4 | INDIA | 168 |
| 10.4.4.1 | High incidence of cancer and increased adoption of biosimilars to fuel market growth | 168 |
| 10.4.5 | AUSTRALIA | 171 |
| 10.4.5.1 | Growing healthcare expenditure to aid market growth | 171 |
| 10.4.6 | SOUTH KOREA | 174 |
| 10.4.6.1 | Well-developed healthcare sector and presence of major pharmaceutical manufacturers to drive market | 174 |
| 10.4.7 | REST OF ASIA PACIFIC | 177 |
| ? | | |
| 10.5 | LATIN AMERICA | 180 |
| 10.5.1 | LATIN AMERICA: RECESSION IMPACT | 180 |
| 10.5.2 | BRAZIL | 183 |
| 10.5.2.1 | Rising incidence of chronic diseases and increasing obesity to augment market growth | 183 |
| 10.5.3 | MEXICO | 186 |
| 10.5.3.1 | Increasing focus of government on healthcare and growing medical tourism to propel market | 186 |
| 10.5.4 | ARGENTINA | 188 |
| 10.5.4.1 | Increasing focus of government on healthcare and growing medical tourism to propel market | 188 |
| 10.5.5 | REST OF LATIN AMERICA | 191 |
| 10.6 | MIDDLE EAST & AFRICA | 194 |
| 10.6.1 | GROWING PUBLIC HEALTHCARE SPENDING TO BOOST MARKET | 194 |
| 10.6.2 | MIDDLE EAST & AFRICA: RECESSION IMPACT | 194 |
| 10.7 | GCC COUNTRIES | 197 |
| 10.7.1 | INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET | 197 |
| 10.7.2 | GCC COUNTRIES: RECESSION IMPACT | 197 |
| 11 | COMPETITIVE LANDSCAPE | 200 |
| 11.1 | OVERVIEW | 200 |
| 11.2 | KEY PLAYER STRATEGIES/RIGHT TO WIN | 200 |
| 11.2.1 | OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PREFILLED SYRINGES MARKET | 201 |
| 11.3 | REVENUE ANALYSIS | 202 |
| 11.4 | MARKET SHARE ANALYSIS | 203 |
| 11.5 | COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 | 205 |
| 11.5.1 | STARS | 205 |
| 11.5.2 | EMERGING LEADERS | 205 |
| 11.5.3 | PERVASIVE PLAYERS | 205 |
| 11.5.4 | PARTICIPANTS | 205 |
| 11.5.5 | COMPANY FOOTPRINT: KEY PLAYERS, 2023 | 207 |
| 11.5.5.1 | Company footprint | 207 |
| 11.5.5.2 | Type footprint | 208 |
| 11.5.5.3 | Material footprint | 209 |
| 11.5.5.4 | Design footprint | 210 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|------------|---|-----|
| 11.5.5.5 | Application footprint | 211 |
| 11.5.5.6 | Region footprint | 212 |
| 11.6 | COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 | 213 |
| 11.6.1 | PROGRESSIVE COMPANIES | 213 |
| 11.6.2 | RESPONSIVE COMPANIES | 213 |
| 11.6.3 | DYNAMIC COMPANIES | 213 |
| 11.6.4 | STARTING BLOCKS | 213 |
| 11.6.5 | COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023 | 215 |
| 11.7 | BRAND/PRODUCT COMPARISON | 216 |
| 11.7.1 | BD | 217 |
| 11.7.2 | GERRESHEIMER AG | 217 |
| 11.7.3 | STEVANATO GROUP | 217 |
| 11.7.4 | SCHOTT GROUP | 217 |
| 11.7.5 | NIPRO | 217 |
| 11.8 | R&D EXPENDITURE | 218 |
| 11.9 | COMPETITIVE SITUATION | 218 |
| 11.9.1 | PRODUCT LAUNCHES | 218 |
| 11.9.2 | DEALS | 220 |
| 11.9.3 | EXPANSIONS | 224 |
| 11.10 | COMPANY VALUATION & FINANCIAL METRICS | 228 |
| 12 | COMPANY PROFILES | 229 |
| 12.1 | KEY PLAYERS | 229 |
| 12.1.1 | BD | 229 |
| 12.1.1.1 | Business overview | 229 |
| 12.1.1.2 | Products offered | 230 |
| 12.1.1.3 | Recent developments | 233 |
| 12.1.1.3.1 | Product launches & approvals | 233 |
| 12.1.1.3.2 | Deals | 233 |
| 12.1.1.3.3 | Expansions | 234 |
| 12.1.1.4 | MnM view | 235 |
| 12.1.1.4.1 | Right to win | 235 |
| 12.1.1.4.2 | Strategic choices | 235 |
| 12.1.1.4.3 | Weaknesses & competitive threats | 235 |
| 12.1.2 | GERRESHEIMER AG | 236 |
| 12.1.2.1 | Business overview | 236 |
| 12.1.2.2 | Products offered | 237 |
| 12.1.2.3 | Recent developments | 238 |
| 12.1.2.3.1 | Deals | 238 |
| 12.1.2.3.2 | Expansions | 239 |
| 12.1.2.4 | MnM view | 239 |
| 12.1.2.4.1 | Right to win | 239 |
| 12.1.2.4.2 | Strategic choices | 239 |
| 12.1.2.4.3 | Weaknesses & competitive threats | 239 |
| 12.1.3 | SCHOTT | 240 |
| 12.1.3.1 | Business overview | 240 |
| 12.1.3.2 | Products offered | 241 |
| 12.1.3.3 | Recent developments | 242 |

| | | |
|-------------|---------------------------------------|-----|
| 12.1.3.3.1 | Expansions | 242 |
| 12.1.3.4 | MnM view | 243 |
| 12.1.3.4.1 | Right to win | 243 |
| 12.1.3.4.2 | Strategic choices | 243 |
| 12.1.3.4.3 | Weaknesses & competitive threats | 243 |
| 12.1.4 | WEST PHARMACEUTICAL SERVICES, INC. | 244 |
| 12.1.4.1 | Business overview | 244 |
| 12.1.4.2 | Products offered | 245 |
| 12.1.4.3 | Recent developments | 246 |
| 12.1.4.3.1 | Deals | 246 |
| 12.1.4.3.2 | Expansions | 247 |
| 12.1.5 | APTARGROUP, INC. | 248 |
| 12.1.5.1 | Business overview | 248 |
| 12.1.5.2 | Products offered | 249 |
| 12.1.5.3 | Recent developments | 250 |
| 12.1.5.3.1 | Deals | 250 |
| 12.1.5.3.2 | Expansions | 250 |
| 12.1.6 | NIPRO | 252 |
| 12.1.6.1 | Business overview | 252 |
| 12.1.6.2 | Products offered | 254 |
| 12.1.7 | BAXTER (SIMTRA) | 255 |
| 12.1.7.1 | Business overview | 255 |
| 12.1.7.2 | Products offered | 256 |
| 12.1.7.3 | Recent developments | 256 |
| 12.1.7.3.1 | Deals | 256 |
| 12.1.7.3.2 | Expansions | 257 |
| 12.1.8 | OWEN MUMFORD LTD. | 258 |
| 12.1.8.1 | Business overview | 258 |
| 12.1.8.2 | Products offered | 258 |
| 12.1.8.3 | Recent developments | 259 |
| 12.1.8.3.1 | Product launches | 259 |
| 12.1.8.3.2 | Deals | 259 |
| 12.1.9 | WEIGAO MEDICAL INTERNATIONAL CO., LTD | 260 |
| 12.1.9.1 | Business overview | 260 |
| 12.1.9.2 | Products offered | 261 |
| 12.1.10 | CREDENCE MEDSYSTEMS, INC. | 262 |
| 12.1.10.1 | Business overview | 262 |
| 12.1.10.2 | Products offered | 262 |
| 12.1.11 | NOVARTIS AG | 263 |
| 12.1.11.1 | Business overview | 263 |
| 12.1.11.2 | Products offered | 264 |
| 12.1.11.3 | Recent developments | 265 |
| 12.1.11.3.1 | Deals | 265 |
| 12.1.12 | STEVANATO GROUP | 266 |
| 12.1.12.1 | Business overview | 266 |
| 12.1.12.2 | Products offered | 267 |
| 12.1.12.3 | Recent developments | 268 |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | |
|-------------|--|-----|
| 12.1.12.3.1 | Product launches | 268 |
| 12.1.12.3.2 | Deals | 269 |
| 12.1.12.3.3 | Expansions | 270 |
| 12.1.13 | POLYMEDICURE | 271 |
| 12.1.13.1 | Business overview | 271 |
| 12.1.13.2 | Products offered | 272 |
| 12.1.14 | MEDXL INC. | 273 |
| 12.1.14.1 | Business overview | 273 |
| 12.1.14.2 | Products offered | 273 |
| 12.1.15 | SHARPS TECHNOLOGY, INC. | 274 |
| 12.1.15.1 | Business overview | 274 |
| 12.1.15.2 | Products offered | 274 |
| 12.2 | OTHER PLAYERS | 275 |
| 12.2.1 | FRESENIUS KABI USA | 275 |
| 12.2.2 | MEDEFIL, INC. | 276 |
| 12.2.3 | D.B.M. S.R.L. | 277 |
| 12.2.4 | TAISEI KAKO CO., LTD. | 278 |
| 12.2.5 | SHANDONG PROVINCE MEDICINAL GLASS CO., LTD. | 279 |
| 12.2.6 | SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD. | 280 |
| 12.2.7 | J.O. PHARMA CO., LTD. (OTSUKA HOLDINGS CO., LTD.) | 281 |
| 12.2.8 | BMI KOREA | 281 |
| 12.2.9 | B. BRAUN SE | 282 |
| 12.2.10 | AL SHIFA MEDICAL PRODUCTS CO. | 283 |
| 13 | APPENDIX | 284 |
| 13.1 | DISCUSSION GUIDE | 284 |
| 13.2 | KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL | 289 |
| 13.3 | CUSTOMIZATION OPTIONS | 291 |
| 13.4 | RELATED REPORTS | 291 |
| 13.5 | AUTHOR DETAILS | 292 |

Prefilled Syringes Market by Type (Conventional, Safety), Material (Glass Prefilled Syringe, Plastic), Design (Single-Chamber Prefilled Syringe, Dual-Chamber), Application (Diabetes, Cancer, and Rheumatoid Arthritis), & Region - Global Forecast to 2030

Market Report | 2024-07-29 | 293 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|-------------------------|------------|
| | Single User | \$4950.00 |
| | Multi User | \$6650.00 |
| | Corporate License | \$8150.00 |
| | Enterprise Site License | \$10000.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|----------------------|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | | |
|-----------|----------------------|-----------|----------------------|
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | 2025-06-26 |
| | | Signature | <input type="text"/> |